1. Home
  2. FBRT vs ANL Comparison

FBRT vs ANL Comparison

Compare FBRT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FBRT

Franklin BSP Realty Trust Inc.

HOLD

Current Price

$8.43

Market Cap

642.6M

Sector

Real Estate

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.12

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBRT
ANL
Founded
2012
2004
Country
United States
United States
Employees
223
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
642.6M
731.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
FBRT
ANL
Price
$8.43
$10.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.50
$20.00
AVG Volume (30 Days)
791.5K
109.1K
Earning Date
04-29-2026
04-10-2026
Dividend Yield
15.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.34
$36.02
Revenue Next Year
$4.95
N/A
P/E Ratio
$13.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.12
$0.88
52 Week High
$11.84
$17.25

Technical Indicators

Market Signals
Indicator
FBRT
ANL
Relative Strength Index (RSI) 46.84 42.01
Support Level $8.35 $9.46
Resistance Level $9.26 $12.59
Average True Range (ATR) 0.22 1.12
MACD 0.01 -0.03
Stochastic Oscillator 54.95 18.21

Price Performance

Historical Comparison
FBRT
ANL

About FBRT Franklin BSP Realty Trust Inc.

Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: